Cutler Group’s Immunome IMNM Stock Holding History

Cutler Group’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,700	Closed	-$2K	–	4031
2023 Q2	$2K	Buy	+4,700	New	+$25.7K	﹤0.01%	3037

Other funds holding IMNM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

PCM

Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cutler Group's IMNM Position: Q3 2023 in Review

Cutler Group sold out of Immunome (IMNM) in Q3 2023, closing a stake of 600 shares — an estimated $4K sold.

Cutler Group first reported a position in IMNM in Q3 2021 and held it in 2 quarters. The position peaked at $17K in Q3 2021. 35 funds tracked by Wall St. Rank hold IMNM as of Q3 2023.

Cutler Group reported no remaining Immunome position as of Q3 2023 after selling out during the quarter.
Cutler Group sold 600 Immunome shares in Q3 2023, an estimated $4K.
Cutler Group first reported a position in Immunome in Q3 2021 and held it in 2 quarters.
Cutler Group's Immunome position peaked at $17K in Q3 2021.
35 funds tracked by Wall St. Rank held Immunome as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.